NWG vs. GSK
NWG (NatWest Group plc) and GSK (GlaxoSmithKline plc) are both stocks. NWG operates in Banks - Diversified (Financial Services), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, NWG returned 14.32%/yr vs 3.96%/yr for GSK. At a 0.31 correlation, their price movements are largely independent.
Performance
NWG vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NWG achieves a -5.66% return, which is significantly lower than GSK's 3.01% return. Over the past 10 years, NWG has outperformed GSK with an annualized return of 14.32%, while GSK has yielded a comparatively lower 3.96% annualized return.
NWG
- 1D
- -1.98%
- 1M
- 4.97%
- YTD
- -5.66%
- 6M
- -0.96%
- 1Y
- 16.03%
- 3Y*
- 42.89%
- 5Y*
- 29.37%
- 10Y*
- 14.32%
GSK
- 1D
- 1.47%
- 1M
- -1.55%
- YTD
- 3.01%
- 6M
- 3.15%
- 1Y
- 27.33%
- 3Y*
- 17.89%
- 5Y*
- 4.64%
- 10Y*
- 3.96%
NWG vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NWG NatWest Group plc | -5.66% | 81.29% | 92.31% | -4.69% | 11.23% | 39.24% | -24.92% | 29.18% | -26.25% | 38.16% |
GSK GlaxoSmithKline plc | 3.01% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between NWG and GSK is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2007 | 0.31 |
Fundamentals
NWG:
$31.84B
GSK:
$101.28B
NWG:
$2.95
GSK:
$2.85
NWG:
5.36
GSK:
17.46
NWG:
0.20
GSK:
1.17
NWG:
1.09
GSK:
3.10
NWG:
0.73
GSK:
4.30
NWG:
$29.58B
GSK:
$32.78B
NWG:
$16.97B
GSK:
$23.87B
NWG:
$9.10B
GSK:
$11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NWG vs. GSK — Risk / Return Rank
NWG
GSK
NWG vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NatWest Group plc (NWG) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NWG | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.51 | ||
| Sortino ratioReturn per unit of downside risk | -0.64 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.19 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 0.67 | 1.47 | -0.80 |
| Martin ratioReturn relative to average drawdown | 1.69 | 3.45 | -1.76 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NWG | GSK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.52 | 1.03 | -0.51 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.88 | 0.19 | +0.69 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.37 | 0.17 | +0.20 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.11 | 0.32 | -0.43 |
Drawdowns
NWG vs. GSK - Drawdown Comparison
The maximum NWG drawdown since its inception was -96.96%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for NWG and GSK.
Loading charts...
Drawdown Indicators
| NWG | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.96% | -55.70% | -41.26% |
Max Drawdown (1Y)Largest decline over 1 year | -24.03% | -18.63% | -5.40% |
Max Drawdown (3Y)Largest decline over 3 years | -34.62% | -28.46% | -6.16% |
Max Drawdown (5Y)Largest decline over 5 years | -40.56% | -50.10% | +9.54% |
Max Drawdown (10Y)Largest decline over 10 years | -67.34% | -50.10% | -17.24% |
Current DrawdownCurrent decline from peak | -71.59% | -17.43% | -54.16% |
Average DrawdownAverage peak-to-trough decline | -86.23% | -18.87% | -67.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.53% | 7.94% | +1.59% |
Volatility
NWG vs. GSK - Volatility Comparison
NatWest Group plc (NWG) has a higher volatility of 9.69% compared to GlaxoSmithKline plc (GSK) at 5.40%. This indicates that NWG's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NWG | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.69% | 5.40% | +4.29% |
Volatility (6M)Calculated over the trailing 6-month period | 23.75% | 18.38% | +5.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.20% | 26.84% | +4.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.51% | 25.01% | +8.50% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 38.31% | 22.86% | +15.45% |
Dividends
NWG vs. GSK - Dividend Comparison
NWG's dividend yield for the trailing twelve months is around 5.53%, more than GSK's 3.48% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.48% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
NWG NatWest Group plc | 5.53% | 3.69% | 4.36% | 9.42% | 11.57% | 2.74% | 4.59% | 9.75% | 0.91% | 0.00% | 0.00% | 0.00% |
Financials
NWG vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between NatWest Group plc and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NWG vs. GSK - Profitability Comparison
NWG - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NatWest Group plc reported a gross profit of 4.36B and revenue of 7.39B. Therefore, the gross margin over that period was 59.0%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
NWG - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NatWest Group plc reported an operating income of 2.03B and revenue of 7.39B, resulting in an operating margin of 27.5%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
NWG - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NatWest Group plc reported a net income of 1.51B and revenue of 7.39B, resulting in a net margin of 20.4%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
NWG and GSK have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NWG has higher volatility (9.69%) compared to GSK (5.40%). In terms of maximum drawdown, NWG dropped -96.96% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.03 vs 0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NWG and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer